Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 13 entries
Sorted by: Best Match Show Resources per page
Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection.

Haemophilia : the official journal of the World Federation of Hemophilia

Stedman CAM, Hyland RH, Ding X, Pang PS, McHutchison JG, Gane EJ.
PMID: 26315711
Haemophilia. 2016 Mar;22(2):214-217. doi: 10.1111/hae.12791. Epub 2015 Aug 28.

AIM: People with inherited bleeding disorders have been disproportionally affected by HCV. We assessed the fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) with the NS5B polymerase inhibitor sofosbuvir (SOF) with ribavirin (RBV) in patients with genotype 1 HCV...

Cite
Stedman CAM, Hyland RH, Ding X, et al. Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia. 2015;22(2):214-217doi: 10.1111/hae.12791.
Stedman, C. A. M., Hyland, R. H., Ding, X., Pang, P. S., McHutchison, J. G., & Gane, E. J. (2016). Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia : the official journal of the World Federation of Hemophilia, 22(2), 214-217. https://doi.org/10.1111/hae.12791
Stedman, C A M, et al. "Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection." Haemophilia : the official journal of the World Federation of Hemophilia vol. 22,2 (2016): 214-217. doi: https://doi.org/10.1111/hae.12791
Stedman CAM, Hyland RH, Ding X, Pang PS, McHutchison JG, Gane EJ. Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia. 2016 Mar;22(2):214-217. doi: 10.1111/hae.12791. Epub 2015 Aug 28. PMID: 26315711.
Copy Download .nbib Format: NLM
Is the current standard therapy for hepatitis C of peginterferon and ribavirin an option for patients coinfected with HIV?.

Nature clinical practice. Gastroenterology & hepatology

McHutchison J, Zekry A.
PMID: 16265063
Nat Clin Pract Gastroenterol Hepatol. 2004 Dec;1(2):70-1. doi: 10.1038/ncpgasthep0050.

No abstract available.

Cite
McHutchison J, Zekry A. Is the current standard therapy for hepatitis C of peginterferon and ribavirin an option for patients coinfected with HIV?. Nat Clin Pract Gastroenterol Hepatol. 2004;1(2):70-1doi: 10.1038/ncpgasthep0050.
McHutchison, J., & Zekry, A. (2004). Is the current standard therapy for hepatitis C of peginterferon and ribavirin an option for patients coinfected with HIV?. Nature clinical practice. Gastroenterology & hepatology, 1(2), 70-1. https://doi.org/10.1038/ncpgasthep0050
McHutchison, John, and Zekry, Amany. "Is the current standard therapy for hepatitis C of peginterferon and ribavirin an option for patients coinfected with HIV?." Nature clinical practice. Gastroenterology & hepatology vol. 1,2 (2004): 70-1. doi: https://doi.org/10.1038/ncpgasthep0050
McHutchison J, Zekry A. Is the current standard therapy for hepatitis C of peginterferon and ribavirin an option for patients coinfected with HIV?. Nat Clin Pract Gastroenterol Hepatol. 2004 Dec;1(2):70-1. doi: 10.1038/ncpgasthep0050. PMID: 16265063.
Copy Download .nbib Format: NLM
The MURDOCK Study: a long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health records.

American journal of translational research

Tenenbaum JD, Christian V, Cornish MA, Dolor RJ, Dunham AA, Ginsburg GS, Kraus VB, McHutchison JG, Nahm ML, Newby LK, Svetkey LP, Udayakumar K, Califf RM.
PMID: 22937207
Am J Transl Res. 2012;4(3):291-301. Epub 2012 Jul 23.

BACKGROUND: Facing critically low return per dollar invested on clinical research and clinical care, the American biomedical enterprise is in need of a significant transformation. A confluence of high-throughput "omic" technologies and increasing adoption of the electronic health record...

Cite
Tenenbaum JD, Christian V, Cornish MA, et al. The MURDOCK Study: a long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health records. Am J Transl Res. 2012;4(3):291-301
Tenenbaum, J. D., Christian, V., Cornish, M. A., Dolor, R. J., Dunham, A. A., Ginsburg, G. S., Kraus, V. B., McHutchison, J. G., Nahm, M. L., Newby, L. K., Svetkey, L. P., Udayakumar, K., & Califf, R. M. (2012). The MURDOCK Study: a long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health records. American journal of translational research, 4(3), 291-301.
Tenenbaum, Jessica D, et al. "The MURDOCK Study: a long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health records." American journal of translational research vol. 4,3 (2012): 291-301.
Tenenbaum JD, Christian V, Cornish MA, Dolor RJ, Dunham AA, Ginsburg GS, Kraus VB, McHutchison JG, Nahm ML, Newby LK, Svetkey LP, Udayakumar K, Califf RM. The MURDOCK Study: a long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health records. Am J Transl Res. 2012;4(3):291-301. Epub 2012 Jul 23. PMID: 22937207; PMCID: PMC3426390.
Copy Download .nbib Format: NLM
Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases.

Brain : a journal of neurology

Benatar M, Wuu J, McHutchison C, Postuma RB, Boeve BF, Petersen R, Ross CA, Rosen H, Arias JJ, Fradette S, McDermott MP, Shefner J, Stanislaw C, Abrahams S, Cosentino S, Andersen PM, Finkel RS, Granit V, Grignon AL, Rohrer JD, McMillan CT, Grossman M, Al-Chalabi A, Turner MR.
PMID: 34677606
Brain. 2021 Oct 22; doi: 10.1093/brain/awab404. Epub 2021 Oct 22.

Significant progress has been made in understanding the pre-symptomatic phase of amyotrophic lateral sclerosis (ALS). While much is still unknown, advances in other neurodegenerative diseases offer valuable insights. Indeed, it is increasingly clear that the well-recognized clinical syndromes of...

Cite
Benatar M, Wuu J, McHutchison C, et al. Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain. 2021;doi: 10.1093/brain/awab404.
Benatar, M., Wuu, J., McHutchison, C., Postuma, R. B., Boeve, B. F., Petersen, R., Ross, C. A., Rosen, H., Arias, J. J., Fradette, S., McDermott, M. P., Shefner, J., Stanislaw, C., Abrahams, S., Cosentino, S., Andersen, P. M., Finkel, R. S., Granit, V., Grignon, A. L., Rohrer, J. D., McMillan, C. T., Grossman, M., Al-Chalabi, A., Turner, M. R. (2021). Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain : a journal of neurology, . https://doi.org/10.1093/brain/awab404
Benatar, Michael, et al. "Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases." Brain : a journal of neurology vol. (2021). doi: https://doi.org/10.1093/brain/awab404
Benatar M, Wuu J, McHutchison C, Postuma RB, Boeve BF, Petersen R, Ross CA, Rosen H, Arias JJ, Fradette S, McDermott MP, Shefner J, Stanislaw C, Abrahams S, Cosentino S, Andersen PM, Finkel RS, Granit V, Grignon AL, Rohrer JD, McMillan CT, Grossman M, Al-Chalabi A, Turner MR. Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain. 2021 Oct 22; doi: 10.1093/brain/awab404. Epub 2021 Oct 22. PMID: 34677606.
Copy Download .nbib Format: NLM
Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases.

Brain : a journal of neurology

Benatar M, Wuu J, McHutchison C, Postuma RB, Boeve BF, Petersen R, Ross CA, Rosen H, Arias JJ, Fradette S, McDermott MP, Shefner J, Stanislaw C, Abrahams S, Cosentino S, Andersen PM, Finkel RS, Granit V, Grignon AL, Rohrer JD, McMillan CT, Grossman M, Al-Chalabi A, Turner MR.
PMID: 34677606
Brain. 2021 Oct 22; doi: 10.1093/brain/awab404. Epub 2021 Oct 22.

Significant progress has been made in understanding the pre-symptomatic phase of amyotrophic lateral sclerosis (ALS). While much is still unknown, advances in other neurodegenerative diseases offer valuable insights. Indeed, it is increasingly clear that the well-recognized clinical syndromes of...

Cite
Benatar M, Wuu J, McHutchison C, et al. Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain. 2021;doi: 10.1093/brain/awab404.
Benatar, M., Wuu, J., McHutchison, C., Postuma, R. B., Boeve, B. F., Petersen, R., Ross, C. A., Rosen, H., Arias, J. J., Fradette, S., McDermott, M. P., Shefner, J., Stanislaw, C., Abrahams, S., Cosentino, S., Andersen, P. M., Finkel, R. S., Granit, V., Grignon, A. L., Rohrer, J. D., McMillan, C. T., Grossman, M., Al-Chalabi, A., Turner, M. R. (2021). Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain : a journal of neurology, . https://doi.org/10.1093/brain/awab404
Benatar, Michael, et al. "Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases." Brain : a journal of neurology vol. (2021). doi: https://doi.org/10.1093/brain/awab404
Benatar M, Wuu J, McHutchison C, Postuma RB, Boeve BF, Petersen R, Ross CA, Rosen H, Arias JJ, Fradette S, McDermott MP, Shefner J, Stanislaw C, Abrahams S, Cosentino S, Andersen PM, Finkel RS, Granit V, Grignon AL, Rohrer JD, McMillan CT, Grossman M, Al-Chalabi A, Turner MR. Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain. 2021 Oct 22; doi: 10.1093/brain/awab404. Epub 2021 Oct 22. PMID: 34677606.
Copy Download .nbib Format: NLM
Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis.

Hepatology international

Rowell J, Thompson AJ, Guyton JR, Lao XQ, McHutchison JG, McCarthy JJ, Patel K.
PMID: 21735316
Hepatol Int. 2012 Apr;6(2):475-81. doi: 10.1007/s12072-011-9291-x. Epub 2011 Jul 07.

BACKGROUND: The hepatitis C virus (HCV) is known to disrupt lipid metabolism, making serum lipoprotein levels good candidates to explore as markers of HCV disease progression. Assessment of the major apolipoproteins (Apo) and their relationship to hepatic fibrosis remain...

Cite
Rowell J, Thompson AJ, Guyton JR, et al. Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis. Hepatol Int. 2011;6(2):475-81doi: 10.1007/s12072-011-9291-x.
Rowell, J., Thompson, A. J., Guyton, J. R., Lao, X. Q., McHutchison, J. G., McCarthy, J. J., & Patel, K. (2012). Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis. Hepatology international, 6(2), 475-81. https://doi.org/10.1007/s12072-011-9291-x
Rowell, J, et al. "Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis." Hepatology international vol. 6,2 (2012): 475-81. doi: https://doi.org/10.1007/s12072-011-9291-x
Rowell J, Thompson AJ, Guyton JR, Lao XQ, McHutchison JG, McCarthy JJ, Patel K. Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis. Hepatol Int. 2012 Apr;6(2):475-81. doi: 10.1007/s12072-011-9291-x. Epub 2011 Jul 07. PMID: 21735316.
Copy Download .nbib Format: NLM
Complex Feeding Decisions: Perceptions of Staff, Patients, and Their Families in the Inpatient Hospital Setting.

Gerontology & geriatric medicine

Miles A, Watt T, Wong WY, McHutchison L, Friary P.
PMID: 28680937
Gerontol Geriatr Med. 2016 Aug 22;2:2333721416665523. doi: 10.1177/2333721416665523. eCollection 2016.

No abstract available.

Cite
Miles A, Watt T, Wong WY, et al. Complex Feeding Decisions: Perceptions of Staff, Patients, and Their Families in the Inpatient Hospital Setting. Gerontol Geriatr Med. 2016;2:2333721416665523doi: 10.1177/2333721416665523.
Miles, A., Watt, T., Wong, W. Y., McHutchison, L., & Friary, P. (2016). Complex Feeding Decisions: Perceptions of Staff, Patients, and Their Families in the Inpatient Hospital Setting. Gerontology & geriatric medicine, 22333721416665523. https://doi.org/10.1177/2333721416665523
Miles, Anna, et al. "Complex Feeding Decisions: Perceptions of Staff, Patients, and Their Families in the Inpatient Hospital Setting." Gerontology & geriatric medicine vol. 2 (2016): 2333721416665523. doi: https://doi.org/10.1177/2333721416665523
Miles A, Watt T, Wong WY, McHutchison L, Friary P. Complex Feeding Decisions: Perceptions of Staff, Patients, and Their Families in the Inpatient Hospital Setting. Gerontol Geriatr Med. 2016 Aug 22;2:2333721416665523. doi: 10.1177/2333721416665523. eCollection 2016. PMID: 28680937; PMCID: PMC5486486.
Copy Download .nbib Format: NLM
Dynamics of interferon-specific gene expression in peripheral blood of interferon alfa-naïve patients with genotype 1 chronic hepatitis C infection treated with albumin-interferon alfa.

Hepatology research : the official journal of the Japan Society of Hepatology

Bain VG, Yoshida EM, Kaita KD, Swain MG, Heathcote EJ, Garcia A, Moore PA, Yu R, McHutchison JG, Subramanian GM.
PMID: 16731032
Hepatol Res. 2006 Aug;35(4):256-62. doi: 10.1016/j.hepres.2006.04.005. Epub 2006 May 30.

Albumin-interferon alfa (alb-IFN) is a novel recombinant protein derived from IFNalpha-2b genetically fused to human albumin, which combines in a single polypeptide the antiviral properties of IFNalpha with the long serum half-life of albumin. Interferon alfa (IFNalpha) mediated biological...

Cite
Bain VG, Yoshida EM, Kaita KD, et al. Dynamics of interferon-specific gene expression in peripheral blood of interferon alfa-naïve patients with genotype 1 chronic hepatitis C infection treated with albumin-interferon alfa. Hepatol Res. 2006;35(4):256-62doi: 10.1016/j.hepres.2006.04.005.
Bain, V. G., Yoshida, E. M., Kaita, K. D., Swain, M. G., Heathcote, E. J., Garcia, A., Moore, P. A., Yu, R., McHutchison, J. G., & Subramanian, G. M. (2006). Dynamics of interferon-specific gene expression in peripheral blood of interferon alfa-naïve patients with genotype 1 chronic hepatitis C infection treated with albumin-interferon alfa. Hepatology research : the official journal of the Japan Society of Hepatology, 35(4), 256-62. https://doi.org/10.1016/j.hepres.2006.04.005
Bain, Vincent G, et al. "Dynamics of interferon-specific gene expression in peripheral blood of interferon alfa-naïve patients with genotype 1 chronic hepatitis C infection treated with albumin-interferon alfa." Hepatology research : the official journal of the Japan Society of Hepatology vol. 35,4 (2006): 256-62. doi: https://doi.org/10.1016/j.hepres.2006.04.005
Bain VG, Yoshida EM, Kaita KD, Swain MG, Heathcote EJ, Garcia A, Moore PA, Yu R, McHutchison JG, Subramanian GM. Dynamics of interferon-specific gene expression in peripheral blood of interferon alfa-naïve patients with genotype 1 chronic hepatitis C infection treated with albumin-interferon alfa. Hepatol Res. 2006 Aug;35(4):256-62. doi: 10.1016/j.hepres.2006.04.005. Epub 2006 May 30. PMID: 16731032.
Copy Download .nbib Format: NLM
The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment.

Hepatology communications

Gane EJ, Metivier S, Nahass R, Ryan M, Stedman CA, Svarovskaia ES, Mo H, Doehle B, Dvory-Sobol H, Hedskog C, Lin M, Brainard DM, Yang JC, McHutchison JG, Sulkowski M, Younes Z, Lawitz E.
PMID: 29404477
Hepatol Commun. 2017 Jun 22;1(6):538-549. doi: 10.1002/hep4.1060. eCollection 2017 Aug.

S282T in NS5B is the primary amino acid substitution associated with resistance to sofosbuvir (SOF) but has rarely been detected in patients treated with a SOF-based regimen. Here, the emergence and fitness of the S282T substitution in virologic failure...

Cite
Gane EJ, Metivier S, Nahass R, et al. The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment. Hepatol Commun. 2017;1(6):538-549doi: 10.1002/hep4.1060.
Gane, E. J., Metivier, S., Nahass, R., Ryan, M., Stedman, C. A., Svarovskaia, E. S., Mo, H., Doehle, B., Dvory-Sobol, H., Hedskog, C., Lin, M., Brainard, D. M., Yang, J. C., McHutchison, J. G., Sulkowski, M., Younes, Z., & Lawitz, E. (2017). The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment. Hepatology communications, 1(6), 538-549. https://doi.org/10.1002/hep4.1060
Gane, Edward J, et al. "The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment." Hepatology communications vol. 1,6 (2017): 538-549. doi: https://doi.org/10.1002/hep4.1060
Gane EJ, Metivier S, Nahass R, Ryan M, Stedman CA, Svarovskaia ES, Mo H, Doehle B, Dvory-Sobol H, Hedskog C, Lin M, Brainard DM, Yang JC, McHutchison JG, Sulkowski M, Younes Z, Lawitz E. The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment. Hepatol Commun. 2017 Jun 22;1(6):538-549. doi: 10.1002/hep4.1060. eCollection 2017 Aug. PMID: 29404477; PMCID: PMC5678900.
Copy Download .nbib Format: NLM
Treatment Strategies for Nonresponders to Hepatitis C Antiviral Therapy.

Gastroenterology & hepatology

McHutchison J.
PMID: 28316524
Gastroenterol Hepatol (N Y). 2006 Aug;2(8):561-563.

No abstract available.

Cite
McHutchison J. Treatment Strategies for Nonresponders to Hepatitis C Antiviral Therapy. Gastroenterol Hepatol (N Y). 2006;2(8):561-563
McHutchison, J. (2006). Treatment Strategies for Nonresponders to Hepatitis C Antiviral Therapy. Gastroenterology & hepatology, 2(8), 561-563.
McHutchison, John. "Treatment Strategies for Nonresponders to Hepatitis C Antiviral Therapy." Gastroenterology & hepatology vol. 2,8 (2006): 561-563.
McHutchison J. Treatment Strategies for Nonresponders to Hepatitis C Antiviral Therapy. Gastroenterol Hepatol (N Y). 2006 Aug;2(8):561-563. PMID: 28316524; PMCID: PMC5350249.
Copy Download .nbib Format: NLM
Hepatitis C virus nonstructural protein 5A inhibitors: novel target-now for new trials and new treatment strategies.

Hepatology (Baltimore, Md.)

Thompson AJ, Clark PJ, McHutchison JG.
PMID: 20812360
Hepatology. 2010 Sep;52(3):1162-4. doi: 10.1002/hep.23853.

No abstract available.

Cite
Thompson AJ, Clark PJ, McHutchison JG. Hepatitis C virus nonstructural protein 5A inhibitors: novel target-now for new trials and new treatment strategies. Hepatology. 2010;52(3):1162-4doi: 10.1002/hep.23853.
Thompson, A. J., Clark, P. J., & McHutchison, J. G. (2010). Hepatitis C virus nonstructural protein 5A inhibitors: novel target-now for new trials and new treatment strategies. Hepatology (Baltimore, Md.), 52(3), 1162-4. https://doi.org/10.1002/hep.23853
Thompson, Alex J, et al. "Hepatitis C virus nonstructural protein 5A inhibitors: novel target-now for new trials and new treatment strategies." Hepatology (Baltimore, Md.) vol. 52,3 (2010): 1162-4. doi: https://doi.org/10.1002/hep.23853
Thompson AJ, Clark PJ, McHutchison JG. Hepatitis C virus nonstructural protein 5A inhibitors: novel target-now for new trials and new treatment strategies. Hepatology. 2010 Sep;52(3):1162-4. doi: 10.1002/hep.23853. PMID: 20812360.
Copy Download .nbib Format: NLM
Stability of Estimated Premorbid Cognitive Ability over Time after Minor Stroke and Its Relationship with Post-Stroke Cognitive Ability.

Brain sciences

McHutchison CA, Chappell FM, Makin S, Shuler K, Wardlaw JM, Cvoro V.
PMID: 31121963
Brain Sci. 2019 May 22;9(5). doi: 10.3390/brainsci9050117.

Considering premorbid or "peak" adult intelligence (IQ) is important when examining post-stroke cognition. The stability of estimated premorbid IQ and its relationship to current cognitive ability in stroke is unknown. We investigated changes in estimated premorbid IQ and current...

Cite
McHutchison CA, Chappell FM, Makin S, et al. Stability of Estimated Premorbid Cognitive Ability over Time after Minor Stroke and Its Relationship with Post-Stroke Cognitive Ability. Brain Sci. 2019;9(5)doi: 10.3390/brainsci9050117.
McHutchison, C. A., Chappell, F. M., Makin, S., Shuler, K., Wardlaw, J. M., & Cvoro, V. (2019). Stability of Estimated Premorbid Cognitive Ability over Time after Minor Stroke and Its Relationship with Post-Stroke Cognitive Ability. Brain sciences, 9(5), . https://doi.org/10.3390/brainsci9050117
McHutchison, Caroline A, et al. "Stability of Estimated Premorbid Cognitive Ability over Time after Minor Stroke and Its Relationship with Post-Stroke Cognitive Ability." Brain sciences vol. 9,5 (2019). doi: https://doi.org/10.3390/brainsci9050117
McHutchison CA, Chappell FM, Makin S, Shuler K, Wardlaw JM, Cvoro V. Stability of Estimated Premorbid Cognitive Ability over Time after Minor Stroke and Its Relationship with Post-Stroke Cognitive Ability. Brain Sci. 2019 May 22;9(5). doi: 10.3390/brainsci9050117. PMID: 31121963; PMCID: PMC6562568.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 13 entries